Resveratrol (trans-Resveratrol; SRT501) 是一种天然多酚,具有抗氧化,抗炎,保护心脏和抗癌的特性。 它的靶点广泛,如mTOR、JAK、β-amyloid、Adenylyl cyclase、IKKβ、DNA polymerase。Resveratrol 也是一种特异性的SIRT1活化剂。Resveratrol 是有效的孕烷 X 受体 (PXR) 抑制剂。Resveratrol 是一种Nrf2激活剂,在小鼠模型中可以改善衰老相关的进行性肾损伤。Resveratrol 作用于内皮细胞促进 NO 产生。
生物活性 | Resveratrol (trans-Resveratrol; SRT501), a natural polyphenolic phytoalexin that possesses anti-oxidant, anti-inflammatory, cardioprotective, and anti-cancer properties. Resveratrol (SRT 501) has a wide spectrum of targets includingmTOR,JAK,β-amyloid,Adenylyl cyclase,IKKβ,DNA polymerase. Resveratrol also is a specificSIRT1activator[1][2][3][4]. Resveratrol is a potent pregnane X receptor (PXR) inhibitor[5]. Resveratrol is anNrf2activator, ameliorates aging-related progressive renal injury in mice model[6]. Resveratrol increases production of NO in endothelial cells[7]. |
IC50& Target[1] | Adenylyl cyclase 0.8 nM (IC50) | IKKβ 1 μM (IC50) | DNA polymerase α 3.3 μM (IC50) | DNA polymerase δ 5 μM (IC50) | Autophagy | Mitophagy | Sirtuin |
|
体外研究 (In Vitro) | Resveratrol (trans-Resveratrol; SRT501) is one of the numerous polyphenolic compounds found in several vegetal sources In the vast majority of cases, Resveratrol displays inhibitory/activatory effects in the micromolar range, which is potentially attainable pharmacologically, although targets with affinities in the nanomolar range have also been reported[1]. MCF-7 cells are plated in DME-F12 medium supplemented with 5% FBS in the presence of increasing concentrations of Resveratrol. Control cells are treated with the same volume of vehicle only (0.1% ethanol). Resveratrol inhibits the growth of MCF-7 cells in a dose-dependent fashion. Addition of 10 μM Resveratrol results in an 82% inhibition of MCF-7 cell growth after 6 days while at 1 μM, only a 10% inhibition is observed. The cells treated with 10 μM Resveratrol have a doubling time of 60 hr whereas control cells doubled every 30 hr. Trypan blue exclusion assay shows that at concentrations of 10 μM or lower, Resveratrol does not affect cell viability (90% viable cells) whereas at 100 μM, only 50% of the cells are viable after 6 days of Resveratrol treatment. Moreover, MCF-7 cells do not undergo apoptosis after incubation with Resveratrol at concentration of 10 μM as determined by ApoAlert Annexin V Apoptosis kit[2]. Resveratrol increases the production of nitric oxide (NO) in endothelial cells by upregulating the expression of endothelial NO synthase (eNOS), stimulating eNOS enzymatic activity, and preventing eNOS uncoupling[7].
|
体内研究 (In Vivo) | The average tumor volume is reduced by treatment with Resveratrol (trans-Resveratrol; SRT501) at a dose of 50 mg/kg body weight (195.5±124.8 mm3; P<0.05) or 100 mg/kg body weight (81.7±70.5 mm3; P<0.001) compare with the vehicle-treated animals (315±94 mm3). There is a good correlation between the tumor volume and the tumor mass[3].
|
Clinical Trial | |
分子量 | |
性状 | |
Formula | |
CAS 号 | |
中文名称 | |
结构分类 | |
运输条件 | Room temperature in continental US; may vary elsewhere. |
储存方式 | Powder | -20°C | 3 years | | 4°C | 2 years | In solvent | -80°C | 6 months | | -20°C | 1 month |
|
溶解性数据 | In Vitro: DMSO : 100 mg/mL(438.14 mM;Need ultrasonic) Ethanol : 50 mg/mL(219.07 mM;Need ultrasonic) 配制储备液 1 mM | 4.3814 mL | 21.9068 mL | 43.8135 mL | 5 mM | 0.8763 mL | 4.3814 mL | 8.7627 mL | 10 mM | 0.4381 mL | 2.1907 mL | 4.3814 mL |
*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80℃, 6 months; -20℃, 1 month。-80℃ 储存时,请在 6 个月内使用,-20℃ 储存时,请在 1 个月内使用。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百 分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶 1. 请依序添加每种溶剂: 0.5%CMC-Na/saline water Solubility: 16.67 mg/mL (73.04 mM); Suspended solution; Need ultrasonic 2. 请依序添加每种溶剂: 50%PEG300 50% saline Solubility: 12.5 mg/mL (54.77 mM); Suspended solution; Need ultrasonic 3. 请依序添加每种溶剂: 10% EtOH 40%PEG300 5%Tween-80 45% saline Solubility: 5 mg/mL (21.91 mM); Clear solution; Need ultrasonic
此方案可获得 5 mg/mL (21.91 mM) 的澄清溶液。 以 1 mL 工作液为例,取 100 μL 50.0 mg/mL 的澄清 EtOH 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。 4. 请依序添加每种溶剂: 10% EtOH 90% (20%SBE-β-CDin saline) Solubility: 5 mg/mL (21.91 mM); Clear solution; Need ultrasonic
此方案可获得 5 mg/mL (21.91 mM) 的澄清溶液。 以 1 mL 工作液为例,取 100 μL 50.0 mg/mL 的澄清 EtOH 储备液加到 900 μL20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。 5. 请依序添加每种溶剂: 10% EtOH 90%corn oil Solubility: ≥ 5 mg/mL (21.91 mM); Clear solution
此方案可获得 ≥ 5 mg/mL (21.91 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。 以 1 mL 工作液为例,取 100 μL 50.0 mg/mL 的澄清 EtOH 储备液加到 900 μL玉米油中,混合均匀。 6. 请依序添加每种溶剂: 10% DMSO 40%PEG300 5%Tween-80 45% saline Solubility: ≥ 2.5 mg/mL (10.95 mM); Clear solution
此方案可获得 ≥ 2.5 mg/mL (10.95 mM,饱和度未知) 的澄清溶液。 以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。 7. 请依序添加每种溶剂: 10% DMSO 90% (20%SBE-β-CDin saline) Solubility: ≥ 2.5 mg/mL (10.95 mM); Clear solution
此方案可获得 ≥ 2.5 mg/mL (10.95 mM,饱和度未知) 的澄清溶液。 以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。 8. 请依序添加每种溶剂: 10% DMSO 90%corn oil Solubility: ≥ 2.5 mg/mL (10.95 mM); Clear solution
此方案可获得 ≥ 2.5 mg/mL (10.95 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。 以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。 9. 请依序添加每种溶剂: 5% DMSO 40%PEG300 5%Tween-80 50% saline Solubility: ≥ 2.5 mg/mL (10.95 mM); Clear solution 10. 请依序添加每种溶剂: 5% DMSO 95% (20%SBE-β-CDin saline) Solubility: ≥ 2.5 mg/mL (10.95 mM); Clear solution *以上所有助溶剂都可在本网站选购。
|